NCT01166490 (Clinical Trial/ ASG-5ME)

Study Title
A Phase 1 Dose Escalation Trial of ASG-5ME in Pancreatic or Gastric Adenocarcinoma (NCT01166490)

Trial Description
This is a phase 1, open-label, dose-escalation clinical trial to evaluate the safety and tolerability of ASG-5ME and identify the maximum tolerated dose in patients with pathologically confirmed metastatic pancreatic adenocarcinoma, and to evaluate safety and tolerability in patients with relapsed or refractory gastric adenocarcinoma. This trial is sponsored by Seattle Genetics. [1]

Study Data

  • Condition: Pancreatic or Gastric Adenocarcinoma
  • Interventions:
    • Drugs used in this trial
      • ASG-5ME
  • Phase: I
  • Enrollment: 51
  • Start: July 2010
  • Completion: July 2013
  • Last verified: August 2013

Study Schematic

(Coming soon)

Click here to Return to Drug map


Last Editorial review: September 3, 2015
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.